The Medical Letter on Drugs and Therapeutics
Seasonal Trivalent Influenza Vaccine for 2010-2011
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of influenza.

VACCINE COMPOSITION — This year’s seasonal trivalent influenza vaccine contains the 2009 pandemic influenza A (H1N1) antigen that was in last year’s monovalent vaccine, A/California/7/2009 H1N1-like, and the same B strain that was in last year’s seasonal trivalent vaccine, B/Brisbane/60/2008-like. It also contains a new H3N2 antigen, A/Perth/16/2009 H3N2-like.1

WHO SHOULD BE VACCINATED — The Advisory Committee for Immunization Practices (ACIP) now recommends vaccination for everyone ≥6 months old without a specific contraindication, including pregnant women.1 Vaccination of pregnant women not only protects them but also ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Seasonal Trivalent Influenza Vaccine for 2010-2011
Article code: 1348a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian